search results for: Axovant

The End­points Slack in­ter­view: Roivant CEO Matt Gline on play­ing mon­ey­ball in phar­ma, Vivek and pol­i­tics, and the $7B ...

5 months ago
People

Jim Mom­tazee's Pa­tient Square leads $150M+ ad­di­tion to Kriya Ther­a­peu­tic­s' 'main­stream' gene ther­a­py am­bi­tions

9 months ago
Financing
Startups

Bit­ter­root Bio nabs $145M Se­ries A with a plan to tack­le chal­leng­ing can­cer tar­get for heart med­i­cines

10 months ago
Financing
Startups

Vivek Ra­maswamy is run­ning an an­ti-“woke,” an­ti-Chi­na pres­i­den­tial cam­paign. It's a con­trast to his time as CEO

11 months ago
People
Pharma

With Boehringer In­gel­heim’s help, Roivant churns out an­oth­er Vant to go up against En­deav­or, Im­pact founders

Last year
Financing
Startups

De­spite mid-stage plaque pso­ri­a­sis win, J&J ap­pears un­de­cid­ed on PhI­II for part­ner's IL-23 drug

Last year
R&D

Vivek Ra­maswamy launch­es bid for US pres­i­den­cy, re­signs from Roivant board

Last year
People

Vivek Ra­maswamy plan­ning a run for US pres­i­dent — re­port

Last year
People

Am­gen to buy Hori­zon for $28B; Mer­ck, Mod­er­na tout can­cer vac­cine; FDA ap­proves sec­ond KRAS drug; and more

Last year
Weekly

Scoop: As Sio clos­es, for­mer CEO from ‘vant ex­it finds him­self at helm of Irv Weiss­man stealth biotech

Last year
Startups
R&D

Sio fails to find buy­er, end­ing 'vant jour­ney in liq­ui­da­tion

Last year
R&D

With new CEO, Pas­sage Bio gives ear­ly look at first six pa­tients in GM1 gan­gliosi­do­sis gene ther­a­py tri­al

Last year
R&D
Cell/Gene Tx

Bio­gen, Ei­sai re­fresh amy­loid hy­poth­e­sis with PhI­II show­ing Alzheimer's med slows cog­ni­tive de­cline

Last year
R&D

Fol­low­ing pro­gram cuts and amid drug launch, Roivant lines up $1B shelf reg­is­tra­tion

Last year
Financing

Scoop: A small gene ther­a­py biotech, flush with ex-Sarep­ta and blue­bird lead­ers, guts CMC

Last year
People
Cell/Gene Tx

FDA places par­tial clin­i­cal hold on David Hung biotech af­ter cer­tain can­cer pa­tients ex­pe­ri­ence eye in­flam­ma­tion

Last year
R&D
FDA+

With $270M in new funds, Shankar Ra­maswamy looks be­yond Roivant in scal­ing his gene ther­a­py 'con­sol­i­dat­ed en­gine'

Last year
Financing
Startups

Your guide to phar­ma Q1 num­bers; Un­pack­ing top 15 R&D gi­ants; Se­cret PhI­II fail­ures; 'Weirdo sci­ence' and ...

Last year
Weekly
1234 Next page Last page

latest

Most read

Drug and biotech com­pa­nies join lob­by­ing push on Chi­na bill as scruti­ny of WuXi con­tin­ues

15 hours ago
China
Pharma

Astel­las' Friedre­ich’s atax­ia gene ther­a­py cleared for clin­i­cal study af­ter ear­li­er ver­sion stum­bled

1 hour ago
R&D
Cell/Gene Tx

Wal­greens will build out spe­cial­ty phar­ma­cy busi­ness, lean­ing in­to drug and ther­a­py ser­vices

3 hours ago
Cell/Gene Tx
Health Tech

Bio­Mar­in's Roc­ta­vian strug­gles con­tin­ue. Is a di­vest­ment in the fu­ture?

4 hours ago
Pharma
Cell/Gene Tx

Cidara buys back flu rights, sells an­ti­fun­gal and inks $240M PIPE

10 hours ago
Financing
Deals
see latest stream
A service from the Financial Times